文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病造血干细胞移植与细胞治疗

骨髓增生异常综合征:2026年诊断、风险分层与管理更新

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.
PubMed 文献 · Am J Hematol · 2026-07-03

本文综述了MDS(现称骨髓增生异常性肿瘤)的诊断、风险分层和治疗进展。诊断基于骨髓形态学异型增生,风险分层常用IPSS-R和IPSS-M。治疗按风险分层选择,低危目标为减少输血和改善生存,高危为延长生存;2020年FDA批准luspatercept和口服地西他滨/cedazuridine,2024年批准imetelstat用于输血依赖低危MDS,异基因移植仍是唯一治愈手段。

要点

  • MDS诊断依据骨髓形态学异型增生,2022年WHO分类更名为骨髓增生异常性肿瘤。
  • 风险分层常用IPSS-R和IPSS-M,均纳入血细胞减少、骨髓原始细胞比例和细胞遗传学。
  • 低危MDS治疗目标为减少输血和改善生存,高危为延长生存;异基因移植是唯一治愈手段。

核心结论

  • MDS治疗需根据风险分层、输血需求、骨髓原始细胞比例、遗传学及突变谱、合并症和移植可能性个体化选择。
  • 低危MDS治疗目标为减少输血需求、降低向高危疾病或AML转化风险并改善生存;高危MDS目标为延长生存。
  • 异基因造血干细胞移植仍是MDS唯一的治愈性手段。

研究设计与样本

  • 本文为综述,系统总结了MDS的诊断、风险分层和治疗进展,检索范围未在摘要中明确报告。

主要发现

  • MDS在老年男性和既往接受细胞毒性治疗者中更常见。
  • IPSS-R和IPSS-M是最常用的预后评分系统,均分析外周血细胞减少、骨髓原始细胞百分比和细胞遗传学特征。
  • 2020年美国批准luspatercept和口服地西他滨/cedazuridine用于MDS患者,2024年批准imetelstat用于输血依赖的低危MDS。
  • 截至本报告,多项联合治疗研究已完成,但均未显示优于单药阿扎胞苷。
  • 对于进展性或难治性疾病,尤其HMA治疗失败后,尚无获批干预措施。

关键数值与推荐

  • MDS诊断基于骨髓涂片和活检的形态学异型增生证据,核型、流式细胞术和分子遗传学通常为补充。
  • 2022年WHO分类将MDS命名为骨髓增生异常性肿瘤(myelodysplastic neoplasms)。
  • 风险分层常用IPSS-R和IPSS-M,纳入外周血细胞减少、骨髓原始细胞百分比和细胞遗传学特征。
  • 低危MDS治疗目标为减少输血需求、降低向高危疾病或AML转化风险并改善生存;高危MDS目标为延长生存。

临床怎么用

  • 临床应基于骨髓形态学、核型、流式细胞术和分子遗传学综合诊断MDS。
  • 使用IPSS-R或IPSS-M进行风险分层,并结合输血需求、骨髓原始细胞比例、遗传学及突变谱、合并症和移植可能性选择治疗。
  • 低危MDS可选用luspatercept、来那度胺、生长因子等;高危MDS可选用HMA、强化化疗或异基因移植。
  • 输血依赖的低危MDS可考虑imetelstat;HMA失败后的进展或难治患者尚无获批干预,应优先考虑临床试验。

局限性

  • 本文为综述,未报告系统检索策略和纳入研究的方法学质量评价。
  • 联合治疗研究均未显示优于单药阿扎胞苷,进展或难治性MDS(尤其HMA失败后)缺乏获批干预措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy. DIAGNOSIS: Diagnosis of MDS is based on morphological evidence of dysplasia upon visual examination of a bone marrow aspirate and biopsy. Information obtained from additional studies such as karyotype, flow cytometry, and molecular genetics is usually complementary and may help refine diagnosis. Under the 2022 WHO classification of MDS, this entity is now termed myelodysplastic neoplasms. RISK-STRATIFICATION: Prognosis of patients with MDS can be calculated using a number of scoring systems. All these scores include analysis of peripheral cytopenias, percentage of blasts in the bone marrow, and cytogenetic characteristics. The most commonly used systems are the Revised International Prognostic Scoring System (IPSS-R) and the molecular IPSS-M. RISK-ADAPTED THERAPY: Therapy is selected based on risk, transfusion needs, percent of bone marrow blasts, cytogenetic and mutational profiles, comorbidities, potential for allogeneic stem cell transplantation (alloSCT), and prior exposure to hypomethylating agents (HMA). Goals of therapy are different in lower-risk patients than in higher-risk and in those with HMA failure. In lower risk, the goal is to decrease transfusion needs and transformation to higher-risk disease or AML, as well as to improve survival. In higher-risk, the goal is to prolong survival. In 2020, two agents were approved in the US for patients with MDS: luspatercept and oral decitabine/cedazuridine. Imetelstat was approved in 2024 for transfusion-dependent lower-risk MDS. Other available therapies include growth factors, lenalidomide, HMAs, intensive chemotherapy, and alloSCT. A number of combinations studies have been completed at the time of this report; none of them was superior to single-agent azacitidine. There are no approved interventions for patients with progressive or refractory disease, particularly after HMA-based therapy. AlloSCT still remains the only curative approach in MDS.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Garcia-Manero G. Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management. Am J Hematol. 2026. PMID: 42400116. doi:10.1002/ajh.70405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。